3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
5
Thoracic
2
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
73
Nivolumab
27
atezolizumab
15
Docetaxel
10
Cyclophosphamide
10
cemiplimab
9
Ipilimumab
9
Paclitaxel
8
Interleukin-2
8
Biopsy
7
fludarabine
6
durvalumab
6
avelumab
6
Taxes
6
Specimen Handling
6
epacadostat
5
Magnetic Resonance Spectroscopy
5
Immune Checkpoint Inhibitors
5
Gemcitabine
5
Drug Therapy
5
Cisplatin
5
Carboplatin
5
spartalizumab
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
Cetuximab
4
utomilumab
3
trametinib
3
poly ICLC
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
naporafenib
×
Head & Neck
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled